Global Authorship Representation in Otolaryngology Clinical Trials

被引:0
|
作者
Yang, Hong-Ho [1 ]
Huynh, Jeffrey D. [2 ]
Moffatt, Clare [1 ]
Patterson, Rolvix H. [3 ]
Xu, Mary Jue [4 ]
St. John, Maie [5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Stanford Univ, Sch Med, Palo Alto, CA USA
[3] Duke Univ, Dept Head & Neck Surg & Commun Sci, Sch Med, Durham, NC USA
[4] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA USA
来源
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY | 2025年 / 10卷 / 02期
基金
美国国家卫生研究院;
关键词
authorship diversity; clinical trials; disparities; global equity; otolaryngology journals; RANDOMIZED CONTROLLED-TRIALS; BIAS; HEAD;
D O I
10.1002/lio2.70092
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: To investigate global authorship representation in clinical trials published in major general otolaryngology journals over the past two decades. Methods: We conducted a bibliometric analysis of clinical trials published in four major general otolaryngology journals between 2000 and 2020. The affiliated nationalities of authors in leading positions (first, senior, corresponding) were reviewed for each trial. Countries were classified by World Bank income group. The temporal trajectory of representation was estimated in multivariable logistic regression models, adjusting for publication environment and study design. The academic impact of trials across income groups was also compared. Results: Among 1432 trials, the leading authors for most were affiliated with non-USA nations (57%) and high-income countries (HIC) (87%). Trials led by authors from upper-middle income countries (UMIC), lower-middle income countries (LMIC), and low-income countries (LIC) were severely underrepresented (11%, 3%, 0%, respectively). Over time, non-USA representation increased (+0.5%, 95% CI [+0.13%, +0.92%] per year), HIC representation decreased (-0.45% [-0.77%, -0.12%]), UMIC representation remained stable (0.19% [-0.13%, 0.51%]), LMIC representation mildly increased (0.26% [0.16%, 0.35%]), and LIC representation remained absent (0%). UMIC author-led trials (aIRR 0.80 [0.68, 0.94]) received significantly fewer citations compared to HIC author-led trials regardless of study design and publication year. Conclusions: The clinical trial literature in the four most widely circulated OHNS journals is dominated by HIC authorship, with only marginal growth in LMIC contributions and no representation from LICs over the past two decades. This underrepresentation may impact the applicability of clinical guidelines in lower-income regions.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Reporting of Clinical Trials: Publication, Authorship, and Trial Registration
    Bonita, Raphael E.
    Adams, Suzanne
    Whellan, David J.
    HEART FAILURE CLINICS, 2011, 7 (04) : 561 - +
  • [12] Authorship issues in multi-centre clinical trials: the importance of making an authorship contract
    Rosenberg, Jacob
    Burcharth, Jakob
    Pommergaard, Hans-Christian
    Vinther, Siri
    DANISH MEDICAL JOURNAL, 2015, 62 (02):
  • [13] Representation of the elderly in cardiovascular clinical trials
    Lee, PY
    Alexander, KP
    Hammill, BG
    Pasquali, SK
    Peterson, ED
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 497A - 497A
  • [14] MINORITY REPRESENTATION IN CARDIOVASCULAR CLINICAL TRIALS
    Ceron, Carlos
    Vilcant, Viliane
    Verma, Gagan
    Zeltser, Roman
    Makaryus, Amgad
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 3045 - 3045
  • [15] The evolution of clinical trials: inclusion and representation
    Rochon, PA
    Berger, PB
    Gordon, M
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1998, 159 (11) : 1373 - 1374
  • [16] A roadmap for improving representation in clinical trials
    Petrik, Amanda F.
    Henrikson, Nora B.
    Coronado, Gloria D.
    Keast, Erin
    Banegas, Matthew P.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 42
  • [17] Collaboration and Authorship of High-Impact Randomized Clinical Trials
    Jackie Marchington
    Art Gertel
    Cindy W. Hamilton
    Journal of General Internal Medicine, 2016, 31 : 11 - 11
  • [18] Development of an authorship algorithm for industry-sponsored clinical trials
    Fusaro, Gina
    Matheis, Robert
    Weigel, Al
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 : S13 - S13
  • [19] Gender and disparity in authorship: An analysis of dermatology randomized clinical trials
    Ricardo, Jose W.
    Shab, Asgha
    Qiu, Yuqing
    Lipner, Shari R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 228 - 231
  • [20] Honorary and ghost authorship in reports of randomised clinical trials in oncology
    Vera-Badillo, Francisco Emilio
    Napoleone, Marc
    Krzyzanowska, Monika K.
    Alibhai, Shabbir M. H.
    Chan, An-Wen
    Ocana, Alberto
    Templeton, Arnoud J.
    Seruga, Bostjan
    Amir, Eitan
    Tannock, Ian F.
    EUROPEAN JOURNAL OF CANCER, 2016, 66 : 1 - 8